A comprehensive bone health management approach for men with prostate cancer receiving androgen deprivation therapy

C.E. Lee, W.D. Leslie, P. Czaykowski, J. Gingerich, M. Geirnaert, Y.K.J. Lau


For advanced and metastatic prostate cancer, androgen deprivation therapy (ADT) is the mainstay of treatment. There is increasing awareness of potential bone health complications as a consequence of ADT use. Many studies have shown that prolonged ADT leads to significant bone loss and increased fracture risk that negatively impact the quality of life in these men. Clinical practice guidelines for preserving bone health in men with prostate cancer on ADT vary across Canada, with no uniform standard. This paper reviews recent studies on bone health and its management in men with prostate cancer receiving ADT, the evidence regarding current management options, and the different provincial guidelines in Canada. Based on this narrative review, we provide general bone health management recommendations for men with prostate cancer receiving ADT.

Full Text:


DOI: http://dx.doi.org/10.3747/co.v18i4.746

Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)